Loading
Virogin Biotech makes oncolytic viruses: modified herpes viruses that infect and break open cancer cells and alert the immune system. Its medicines are in trials in liver and bile duct cancers and other advanced solid tumours.
Virogin Biotech describes itself as a clinical-stage immuno-oncology company combining oncolytic virotherapy with mRNA vaccines in a prime-boost approach; it states it was founded in Canada in 2015 and lists offices in Richmond, British Columbia, and Shanghai. Its registered programmes include VG161, studied since 2021 by its Shanghai affiliate in advanced solid tumours, primary liver cancer, sarcoma and intrahepatic cholangiocarcinoma, and VG2025, a recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1. Under the sponsor name Virogin Biotech Ltd. it registered a phase 2 trial of VG2025 in intrahepatic cholangiocarcinoma (NCT07522476, posted April 2026) and a phase 1/2 trial of intravenous VG2025 in advanced solid tumours (NCT07682870). Its first registered cancer trial under any Virogin sponsor name, NCT04758897 (VG161 in advanced solid tumours, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.), was posted on ClinicalTrials.gov in February 2021.
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/